ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

11024	Companies
241652	Keywords
170130	Articles
130104	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 06/20/2025 at 19:30, 1 year 2 months ago

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
OSE Immunotherapeutics reaffirms commitment to transparent and serene General Meeting in compliance with market rules, providing 'Questions and Answers' document for shareholders

Shareholders Transparency General Meeting OSE Immunotherapeutics Market Rules
BRIEF

published on 06/19/2025 at 15:58, 1 year 2 months ago

Strategic change within OSE Immunotherapeutics

Board Of Directors General Meeting Crossing Thresholds OSE Immunotherapeutics Shareholders' Agreement
BRIEF

published on 04/30/2025 at 07:35, 1 year 4 months ago

OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

Immuno-oncology Personalized Treatment Immune Checkpoint Blockade Gene Expression Signature Cancer Prediction
PRESS RELEASE

published on 04/30/2025 at 07:30, 1 year 4 months ago

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
OSE Immunotherapeutics and Léon Bérard Cancer Center present a new gene expression signature for predicting clinical response to immune checkpoint at AACR Annual Meeting 2025

AACR Annual Meeting OSE Immunotherapeutics Gene Expression Signature Léon Bérard Cancer Center Clinical Response Prediction
BRIEF

published on 04/09/2025 at 07:35, 1 year 5 months ago

OSE Immunotherapeutics to Present Data on Lusvertikimab at DDW 2025

Ulcerative Colitis OSE Immunotherapeutics Lusvertikimab Phase 2 Extension DDW 2025
PRESS RELEASE

published on 04/09/2025 at 07:30, 1 year 5 months ago

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025
OSE Immunotherapeutics to present new data on Lusvertikimab's long-term benefits and safety in ulcerative colitis at DDW 2025, showcasing potential in autoimmune diseases

Ulcerative Colitis Immuno-oncology Inflammatory Diseases OSE Immunotherapeutics Lusvertikimab
BRIEF

published on 11/04/2024 at 07:35, 1 year 10 months ago

OSE Immunotherapeutics Reveals Promising Phase 2 Results for Ulcerative Colitis Treatment

Ulcerative Colitis Phase 2 Study OSE Immunotherapeutics Clinical Results Lusvertikimab
PRESS RELEASE

published on 11/04/2024 at 07:30, 1 year 10 months ago

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics reports positive results from Phase 2 study of Lusvertikimab for Ulcerative Colitis treatment. Primary endpoint met with high clinical and endoscopic remission rates

Positive Results Phase 2 Study OSE Immunotherapeutics Lusvertikimab Ulcerative Colitis Treatment
BRIEF

published on 09/10/2024 at 07:35, 2 years ago

OSE Immunotherapeutics Launches Phase 3 Study for Tedopi® in Lung Cancer

NSCLC Immunotherapy Phase 3 Trial Cancer Vaccine Global Launch
PRESS RELEASE

published on 09/10/2024 at 07:30, 2 years ago

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
OSE Immunotherapeutics launches international Phase 3 trial 'Artemia' of cancer vaccine Tedopi® in second-line NSCLC treatment, aiming for regulatory approval in Europe and North America

NSCLC Phase 3 Trial OSE Immunotherapeutics Artemia Tedopi

Accesswire

Published on 09/18/2026 at 23:50, 4 minutes ago

Mako Mining Announces Equity Incentive Grants
Published on 09/18/2026 at 22:00, 1 hour 54 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 3 hours 19 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 9 hours 24 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 13:30, 10 hours 24 minutes ago

Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer

View all ACCESSWIRE

EQS Group

Published on 09/18/2026 at 18:45, 5 hours 9 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 5 hours 9 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 5 hours 41 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 5 hours 44 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 5 hours 47 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 5 hours 19 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 6 hours 9 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 6 hours 9 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 6 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 3 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE